Nom du produit:benzyl piperazine-1-carboxylate
IUPAC Name:benzyl piperazine-1-carboxylate
- CAS：31166-44-6
- Formule moléculaire：C12H16N2O2
- Pureté：95%+
- Numéro de catalogue：CM103953
- Poids moléculaire：220.27
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:31166-44-6
- Formule moléculaire:C12H16N2O2
- Point de fusion:-
- Code SMILES:O=C(OCC1=CC=CC=C1)N1CCNCC1
- Densité:
- Numéro de catalogue:CM103953
- Poids moléculaire:220.27
- Point d'ébullition:
- N° Mdl:MFCD00274317
- Stockage:
Category Infos
- Piperazines
- Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- RMC-6236
- Over 30% of all human cancers, including a certain percentage of pancreatic, colorectal, lung cancers, and AML are driven by mutations of RAS genes. There is a significant unmet medical need in RAS mutant cancers.
Revolution Medicines’ investigational drug, RMC-6236 is an oral, non-covalent, RAS (ON) inhibitor that is selective for the active, GTP-bound state of both mutant and wild-type variants of the canonical RAS isoforms. RMC-6236 is under clinical phase I studies as monotherapy in NSCLC and PDAC, and advanced solid tumors harboring KRAS G12X mutations.
Recherche 
+86 21 5895 0110 
